Opening of Bids - Demolition of 921 Louise Street Proj No 125-043A - KLF Enterprises

Home Browse Search

s SAFETY & HEALTH MANUAL C.03.c. Verify a sufficient number of covered employees will be selected for random testing during each calendar year to equal an annual rate not less than the required minimum annual percentage rate (see Protocol C.03.a.) [199.105(c)(6)]. The total number of covered employees eligible for random testing throughout the year will be calculated by adding the total number of covered employees eligible for testing during each random testing period for the year and dividing that total by the number of random testing periods [199.119(c)]. C.03.d. Verify random drug tests are unannounced and that the dates for administering the tests are spread reasonably throughout the calendar year (199.105(c)(7)]. C.04.a. Verify decisions to test are reasonable and articulable, and based on specific contemporaneous physical, behavioral or performance indicators of probable drug use. At least two supervisors, one of whom is trained in detection of the symptoms of drug use, substantiate and concur in the decision to test an employee who is reasonably suspected of drug use [§199.105(d)]. C.05.a. Verify a covered employee that violates DOT drug regulations does not return to duty for a covered function until the employee: 1) Completes a SAP evaluation, referral, and education/treatment process [§40.285(a), §40.289(b), and §199.105(e)]; 2) After completion of the SAP process above, successfully completes a return -to -duty drug test (§40.305(a) and §199.105(e)]; and 3) All return -to -duty testing will be performed under direct observation [§40.67(b)]. C.06.a. Verify SAP will establish a written follow-up testing plan for a covered employee that violates DOT drug regulations and seeks to return to the performance of a covered function [§40.307(a)). All follow-up testing will be performed under direct observation [§40.67(b)]. C.06.b. Verify follow-up testing is performed on an unannounced basis, at a frequency established by the SAP, for a period of not more than 60 months. At least six tests must be conducted within the first 12 months following the covered employee's return to duty. [§40.307, §40.309, and §199.105(f)]. C.07.a. Verify procedures are in place fordirect observation when required under §§40.67(a), (b) and (d). B.02.a. Urine Specimen Collector (§40.33) meet the applicable qualification requirements of Part 40 and Part 199. O.01.a. Does the operator ensure that, unless no other collector is available, an immediate supervisor of an employee does not serve as a collection site person [§40.31(c)]? O.01.b. Do collectors meet the training requirements of §40.33 and is documentation available showing that currently all requirements are met (§40.33(g)]? O.01.c. Does the operator provide error correction training as required by §40.33(f) and does the training occur within 30 days of the date of notification of the error that led to the need for training? O.02.a. Has the employer designated a collection site that meets the requirements of §40.41. O.02.b. If the collection site uses a facility normally used for other purposes, are procedures in place to ensure before the collection that: (1) access to collection materials and specimens is effectively restricted; and (2) the facility is secured against access during the procedure to ensure privacy to the employee and prevent distraction of the collector? Also, are limited -access signs posted [§40.43(c)]? O.02.c. Are procedures in place to assure the collector maintains personal control over each specimen and CCF throughout the collection process and to prevent unauthorized personnel from entering any part of the site in which urine specimens are collected or stored [§40.43(d)(5) and §40.43(e)]? O.02.d. Is the current Federal Drug Testing Custody and Control Form (CCF) or equivalent being used [§40.45]? O.02.e. Is a collection kit used that meets the requirements of Appendix A to Part 40 [§40.49]? O.03.a. Do collection site personnel explain the basic collection procedure to the employee, including showing the employee the instructions on the back of the CCF [§40.61(e)]? O.03.b. Do collection site personnel provide the donor with an individually wrapped or sealed collection container from the collection kit materials [§40.63(c)]? SECTION 42: Anti -Drug & Alcohol Misuse Prevention Plan Program I Page 44 of 49